217 results on '"Rech, Juergen"'
Search Results
2. Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial
3. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial
4. 2023 EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice
5. Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases: results from the interim analysis of the RELIANCE registry
6. Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial
7. Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial
8. Anti-granulocyte-macrophage colony-stimulating factor antibody otilimab in patients with hand osteoarthritis: a phase 2a randomised trial
9. Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study
10. Anti-IL1 Therapy Does Not Affect the Response to SARS-COV-2 Vaccination and Infection in Patients with Systemic Autoinflammatory Diseases
11. Hidradenitis Suppurativa and Concurrent Psoriasis: Comparison of Epidemiology, Comorbidity Profiles, and Risk Factors
12. A comparative analysis of articular bone in large cohort of patients with chronic inflammatory diseases of the joints, the gut and the skin
13. Reversing the Inflammatory Process—25 Years of Tumor Necrosis Factor-α Inhibitors
14. Identification of circulating microRNA patterns in patients in psoriasis and psoriatic arthritis.
15. Organisation einer Studienambulanz und prüfstellenspezifische Formalitäten
16. Presence of HLA-B27 is associated with changes of serum levels of mediators of the Wnt and hedgehog pathway
17. Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation—data from the prospective IVEPSA study
18. Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
19. Concise report: a minimal-invasive method to retrieve and identify entheseal tissue from psoriatic arthritis patients
20. Towards preventive treatment of rheumatoid arthritis
21. Microstructural Bone Changes Are Associated With Broad‐Spectrum Autoimmunity and Predict the Onset of Rheumatoid Arthritis
22. Blockade of TNF-α rapidly inhibits pain responses in the central nervous system
23. Proteomic Approaches to Defining Remission and the Risk of Relapse in Rheumatoid Arthritis
24. New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension
25. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study
26. Genetic Analysis of MPO Variants in Four Psoriasis Subtypes in Patients from Germany
27. MOR103, a human monoclonal antibody to granulocyte–macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial
28. High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission
29. New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension.
30. Differences in bone structure between rheumatoid arthritis and psoriatic arthritis patients relative to autoantibody positivity
31. Correspondence on ‘Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’
32. Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study
33. Rare Loss-of-Function Mutation in SERPINA3 in Generalized Pustular Psoriasis
34. IgA anti-citrullinated protein antibodies are associated with flares during DMARD tapering in rheumatoid arthritis.
35. Time to Flare in Patients With New-Onset Versus Relapsing Giant Cell Arteritis Treated With Tocilizumab or Placebo Plus Prednisone Tapering: 3-Year Results From a Randomized Controlled Phase 3 Trial
36. Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Results from Part 2 of a Randomized Controlled Phase 3 Trial
37. Maintained Benefit in Health-Related Quality of Life of Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Results from the Open-Label, Long-Term Extension of a Phase 3 Randomized Controlled Trial
38. Time to Flare in Patients with New-Onset versus Relapsing Giant Cell Arteritis Treated with Tocilizumab or Placebo Plus Prednisone Tapering: 3-Year Results from a Randomized Controlled Phase 3 Trial
39. Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors
40. Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study
41. Association of brain functional magnetic resonance activity with response to tumor necrosis factor inhibition in rheumatoid arthritis
42. Fulminant course of osteonecrosis of the jaw in a rheumatoid arthritis patient following oral bisphosphonate intake and biologic therapy
43. Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of the erosion
44. Successful treatment of adult-onset Stillʼs disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade
45. Secukinumab leads to shifts from stage-based towards response-based disease clusters- Comparative data from very early and established psoriatic arthritis
46. Blockade of Interleukin-17 Leads to Shifts From Stage-based Towards Response-based Disease Clusters- Comparative Data From Very Early and Established Psoriatic Arthritis
47. Bone Mass, Bone Microstructure and Biomechanics in Patients with Hand Osteoarthritis
48. Proteomic Approaches to Defining Remission and the Risk of Relapse in Rheumatoid Arthritis.
49. LONG-TERM OUTCOME OF TOCILIZUMAB FOR PATIENTS WITH GIANT CELL ARTERITIS: RESULTS FROM PART 2 OF THE GIACTA TRIAL
50. Multicenter Phase II Trial of Immunotherapy With the Humanized Anti-CD22 Antibody, Epratuzumab, in Combination With Rituximab, in Refractory or Recurrent Non-Hodgkinʼs Lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.